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Summary
Cellular senescence is a state of stable proliferation arrest of cells.
The senescence pathway has many beneficial effects and is seen
to be activated in damaged/stressed cells, as well as during
embryonic development and wound healing. However, the
persistence and accumulation of senescent cells in various tissues
can also impair function and have been implicated in the
pathogenesis of many age-related diseases. Osteoarthritis (OA),
a severely debilitating chronic condition characterized by pro-
gressive tissue remodeling and loss of joint function, is the most
prevalent disease of the synovial joints, and increasing age is the
primary OA risk factor. The profile of inflammatory and catabolic
mediators present during the pathogenesis of OA is strikingly
similar to the secretory profile observed in ‘classical’ senescent
cells. During OA, chondrocytes (the sole cell type present within
articular cartilage) exhibit increased levels of various senescence
markers, such as senescence-associated beta-galactosidase (SAb
Gal) activity, telomere attrition, and accumulation of p16ink4a.
This suggests the hypothesis that senescence of cells within joint
tissues may play a pathological role in the causation of OA. In this
review, we discuss the mechanisms by which senescent cells may
predispose synovial joints to the development and/or progres-
sion of OA, as well as touching upon various epigenetic
alterations associated with both OA and senescence.
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Introduction
Osteoarthritis (OA)
Osteoarthritis (OA) is the most prevalent disease of synovial joints
(around 4.7% of global population for knee and hip OA alone), afflicting
many millions worldwide with pain and disability (Cross et al., 2014),
and thus represents an enormous healthcare and socioeconomic burden.
Advancing age is a major risk factor, thus the burden of OA is set to
increase dramatically as populations continue to age. Gender is also
recognized as a contributing factor, with the female population
generally being at a higher risk of developing OA. Females are seen to
develop more severe knee and hand OA compared to their male
counterparts, especially when ≥55 years old (Srikanth et al., 2005). It has
been implied that hormones may play a role in the increased incidence of
OA in females, particularly a postmenopausal decrease in estrogen
levels. Other risk factors contributing to the burden of OA are
summarized in Fig. 1.
A generalized structure for a synovial joint is illustrated in Fig. 2,
characterized by the presence of connective tissues such as articular
cartilage, subchondral bone, ligaments, and in some joints menisci
(fibrocartilage structures that provide stability and load dispersal),
encapsulated by the synovial membrane (Fig. 2A). A joint affected by
OA exhibits progressive degeneration of the articular cartilage, formation
of bony peripheral outgrowths (osteophytes), changes in subchondral
bone and thickening of both the synovium and ligaments (Fig. 2B), and
in many cases synovial inflammation (synovitis), which is thought to be
an important driver of early pathology (Benito et al., 2005). Pathologic
roles for multiple tissues in deteriorating joint function therefore define
OA as a whole joint disease, driven by various biomechanical and
inflammatory factors. There are currently no treatments available to
effectively prevent or reverse progressive joint damage; therefore, new
and innovative treatments are urgently required to improve treatment
options. This will require continued improvements in our understanding
of the molecular mechanisms underlying OA pathology.
Cellular senescence
In 1961, Leonard Hayflick and Paul Moorhead first described the
phenomenon known as ‘cellular senescence’, a form of ‘senescence at
the cellular level’ (Hayflick & Moorhead, 1961), stating that primary
human fibroblasts have a restricted lifespan of around 50 cell divisions in
culture. This was once believed to be purely an in vitro phenomenon
caused by cell culture shock; however, many research groups observed
senescent cells in premalignant tissues, and this was soon discovered to
be an important process in vivo (Dimri et al., 1995; Serrano et al., 1997;
Sherr & DePinho, 2000; Michaloglou et al., 2005; Narita & Lowe, 2005).
Cellular senescence is now considered a signal transduction process that
results in cells entering a stable state of growth arrest while remaining
metabolically active. Senescent cells most commonly enter this stable
state in G1 phase, or early S phase, of the cell cycle (Di Leonardo et al.,
1994; Ogryzko et al., 1996; Serrano et al., 1997; Herbig et al., 2004).
However, senescent cells have also been observed to undergo arrest in
G2 phase (Mao et al., 2012). Senescence ultimately results in the loss of
cellular replicative capacity due to the inability of these cells to express
genes required for proliferation (Dimri et al., 1994, 1996). Senescence is
not characterized by a specific set of markers, but rather by association
with a collection of cellular phenotypes that often coexist in a stressed
cellular environment, such as altered morphology, chromatin structure
and gene expression patterns, and an activated DNA damage response
(d’Adda di Fagagna et al., 2003; Di Micco et al., 2006, 2011; d’Adda di
Fagagna, 2008; Rodier et al., 2009). Senescent cells secrete a variety of
inflammatory cytokines, growth factors and many more soluble and
insoluble factors known as the senescence-associated secretory pheno-
type (SASP) (Campisi, 2005), or the senescence-messaging secretome
(SMS) (Kuilman & Peeper, 2009). These factors are secreted into the cell
microenvironment, with cytokines such as IL-6 and IL-8 enforcing the
stable growth arrest of senescent cells (Acosta et al., 2008; Kuilman
et al., 2008). Various features of senescent cells, such as the SASP, can
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cause damage to surrounding tissue (Burton et al., 2007). SASP secreted
by senescent cells can alter the tissue microenvironment, while the
senescence of stem or progenitor cells can impair tissue regeneration
(Koobatian et al., 2015). Cells undergo senescence in response to
various detrimental stimuli, including but not limited to oncogene
activation; radiation; oxidative stress; shortened telomeres; and unsched-
uled DNA replication. Senescence is known to evoke tumor suppression,
and it is widely accepted that senescence functions as a protective
mechanism against cancer due to its ability to induce the proliferation
arrest of damaged cells (Michaloglou et al., 2005; Dhomen et al., 2009;
Goel et al., 2009). Aside from cancer, senescence-associated growth
arrest is also important in normal physiological processes such as wound
healing (Krizhanovsky et al., 2008).
Over the past decade, many studies have linked cellular senescence to
aging (Krishnamurthy et al., 2004; Baker et al., 2008, 2013, 2016) and
age-related pathologies (Baker et al., 2011), thus leading to an overlap
in research between the fields of disease processes and gerontology.
Cellular senescence and disease
In healthy individuals, the body utilizes various systems that help to
prevent and/or repair cellular, molecular, and physiological damage to
cells. However, these repair systems become progressively weaker during
aging and the organism becomes more vulnerable to the development
of a variety of diseases. Mammals such as mice, baboons, and humans
have been reported to accumulate senescent cells as they age (Dimri
et al., 1995; Krishnamurthy et al., 2004; Jeyapalan et al., 2007).
Moreover, the accumulation of senescent cells in tissues contributes to
both aging and the promotion of age-related diseases (Krishnamurthy
et al., 2004; Baker et al., 2008, 2016). For example, researchers have
observed the presence of senescent cells (endothelial-like cells, vascular
smooth muscle cells, and macrophage-like cells) in mice induced to
develop atherosclerosis (Childs et al., 2016). Senescent vascular
endothelial cells are present in human atherosclerotic lesions and
contribute to atherogenesis (Minamino et al., 2002). In the context of
OA, senescent cells were observed near the osteoarthritic lesions, but
not in intact cartilage from the same patients and normal donors (Price
et al., 2002; Erusalimsky & Kurz, 2005). Consistent with this, trans-
planted senescent cells induce an OA-like state in mice (Xu et al., 2016).
We discuss below the potential mechanisms by which accumulation
of senescent cells may predispose articular joints to the development
and/or progression of OA. We will also discuss the role of epigenetic
changes in senescent cells in the context of OA pathology and highlight
potential epigenetic treatment options.
Senescence in osteoarthritis pathology
Although there are multiple joint tissues and cell types involved in
OA pathology, chondrocytes have been the focus of the vast
majority of studies to date that address a role for senescence.
Chondrocytes are the only cell type present in articular cartilage, a
highly specialized avascular and aneural tissue whose structural and
mechanical properties are largely defined by the two predominant
extracellular matrix (ECM) components, type II collagen, and aggre-
can. Chondrocytes are responsible for producing and maintaining
this ECM and receive nutrients and external chemical signals from
the synovial fluid via secretions of fibroblast-like synoviocytes of the
intimal synovial layer.
Senescent cells exhibit a SASP that enables them to communicate
with other cells, as well as the microenvironment, stimulating neigh-
boring cells to senesce (Acosta et al., 2013). One characteristic feature
of SASP is enhanced production of vascular endothelial growth factor
(VEGF), a signal protein that promotes blood vessel formation via the
processes of vasculogenesis and angiogenesis. VEGF and its cognate
receptors are expressed in OA cartilage and may contribute to
dysregulated osteogenesis and the formation of osteophytes (Pfander
et al., 2001; Hashimoto et al., 2002; Enomoto et al., 2003). Chondro-
cyte SASP is known to include production of matrix-degrading proteases
including the matrix metalloproteinases MMP-1, and -13 (Philipot et al.,
2014). MMP-13 is thought to be central to the irreversible degradation
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Fig. 2 A comparison of a normal ‘healthy’ articular joint with that of a joint with
OA. We also highlight the characteristics of the senescent phenotype that could
potentially play a role in specific alterations seen in OA (seen in blue). (A) A diagram
of a normal healthy joint. (B) A diagram of an OA-affected joint, highlighting
common changes, for example, cartilage degradation; synovial hypertrophy often
accompanied by inflammation (synovitis); formation of peri-articular osteophytes;
osteosclerosis of subchondral bone.
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Fig. 1 Various factors believed to contribute to the onset of OA.
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of the cartilage type II collagen lattice in OA, partly on the basis of
exogenous expression or deficiency in murine studies (Neuhold et al.,
2001; Little et al., 2009).
Obesity is a major risk factor in OA, and oxidative stress resulting from
excess adiposity (Keaney et al., 2003; Furukawa et al., 2004) could
therefore contribute to disease partly through reactive oxygen species
(ROS)-induced pathways. Excess adiposity is also associated with an
increased accumulation of senescent cells and associated SASP factors
(Schafer et al., 2016), as proposed (Tchkonia et al., 2010). Further,
exercise prevents diet-induced cellular senescence as well as the SASP
within visceral adipose tissue (Schafer et al., 2016). This suggests a
possible mechanism whereby exercise-mediated health benefits may be
mediated by the prevention of senescence.
Senescence in OA chondrocytes & cartilage
It is thought that cellular senescence may play a significant role in the
pathology of OA, with OA chondrocytes exhibiting a variety of
senescent-associated phenotypes (discussed below and Fig. 3). Despite
recent traction for views of OA as a whole joint disease rather than
merely dysfunctional cartilage, chondrocytes remain regarded as key
players in OA pathology and are understood to exhibit during disease a
perturbation of the normal balance between synthesis and degradation
of extracellular matrix (ECM) components. This involves upregulating the
production of matrix-degrading metalloproteinases such as MMP-13,
exogenous activity of which was sufficient to recapitulate key OA
features in mice (Neuhold et al., 2001). Senescence of chondrocytes
would be expected to lead similarly to shifting of the balance between
ECM synthesis and degradation, through metalloproteinase components
of the SASP response. Moreover, enhanced degradation of cartilage
ECM by chondrocytes during OA may be partly due to demethylation of
CpG sites in the promoter regions of genes encoding key cartilage-
degrading proteases, and therefore contributing to disease progression
by increasing their production (Roach et al., 2005).
Aging and OA are not always interdependent, and many cases of OA
in younger adults stem from joint injury (Gelber et al., 2000). However,
as cellular senescence can result from a chronically stressed environment,
it remains an interesting possibility that posttraumatic OA may be
characterized or even partly triggered by an accumulation of senescent
cells within damaged tissue. This view was supported, albeit in vitro, by
the observation that mechanical stress accelerated chondrocyte senes-
cence through increased oxidative stress (Martin et al., 2004a). Chon-
drocyte senescence is observed to be triggered by oxidative stress
(Martin et al., 2004b) and is expected to contribute to the abnormal
inflammatory environment present in OA. Chondrocytes exhibit very low
metabolic activity and are well adapted to the hypoxic conditions of the
joint, although exacerbated hypoxia may drive synovial inflammation in
rheumatoid arthritis (RA) (an age-related autoimmune inflammatory joint
disease characterized by joint destruction, chronic inflammation, and
dysfunction of innate and adaptive immune responses) contributing to
pathology (Ng et al., 2010). As synovitis is an acknowledged feature of
OA, it is plausible that enhanced hypoxia could play a similar pathologic
role in this scenario (Giatromanolaki et al., 2003). Similarly, chronic
oxidative stress experienced by other joint tissues during disease may
also lead to cellular senescence.
When compared to isolated chondrocytes from normal cartilage, OA
chondrocytes positively express a variety of senescence-associated
markers, for example, telomere attrition (Martin & Buckwalter, 2001);
activated DNA damage response (DDR); ROS secretion; SAbGal activity
(Price et al., 2002); increased p16ink4a expression (Zhou et al., 2004);
accumulation of MMPs induced by pro-inflammatory cytokines (Bill-
inghurst et al., 1997; Shlopov et al., 1997; Fig. 3). This has led to
speculation that the integrity and function of the cartilage becomes
impaired due in part to the age-related accumulation of senescent
chondrocytes. In 2001, Martin and Buckwalter described telomere
erosion in OA chondrocytes (Martin & Buckwalter, 2001). However, in
normal articular cartilage, the rate of chondrocyte mitosis is very low
(Aigner et al., 2001). This limited proliferative capacity in normal
cartilage would suggest that other stress factors, such as oxidative
stress (Yudoh et al., 2005) and abnormal mechanical loading (Harbo
et al., 2012, 2013), may contribute to the shortening of telomeres of OA
chondrocytes, contributing to pathology via premature senescence.
Premature senescence of chondrocytes could then be a consequence of
both intrinsic (limited replicative capacity in situ) and extrinsic (stress-
induced) factors provoking the age-dependent deterioration of chon-
drocytes. On the other hand, as proliferation of chondrocytes is actually
increased in OA cartilage (Aigner et al., 2001), this might help explain
observed telomere erosion in disease. In knee OA, Gao et al. (2016)
demonstrated a correlation between SAbGal expression and disease
severity of patients. They investigated the levels of SAbGal expression in
normal cartilage compared with OA cartilage of differing severity (mild,
moderate, and severe). In normal articular cartilage, no staining was
observed. However, in lesions taken from mild, moderate, and severely
damaged knee OA cartilage, they observed SAbGal staining in a subset
of chondrocytes close to the lesion. It is important to highlight that the
elevation of SAbGal in cultured cells isolated from diseased joints is not a
reliable indicator of pathological involvement of senescence in vivo.
Hence, more functional experiments are required to investigate role of
senescent cells in the in vivo development of OA.
Chondrocyte turnover is thought be a rare event in cartilage;
however, these cells proliferate when removed from the tissue and
placed in culture. In human OA lesions, senescent cells are often found
near clusters of cells, indicating increased mitotic activity prior to
senescence (Price et al., 2002). Further, senescent cells are known to
accumulate in tissues as we age and the mere presence of them in a
disease context could be a consequence of the normal aging process. For
example, Martin and Buckwalter (2001) showed that an association
between OA and aging is due in part to replicative senescence of
chondrocytes in vivo. However, evidence for direct involvement of
senescent cells in cartilage damage comes from the senescent cell
transplantation mouse model (Xu et al., 2016). In a recent study, Xu
et al. injected either senescent or nonsenescent cells into the knee joint
area of mice. Authors showed that transplanting senescent cells into the
knee region caused pathological features suggestive of OA (Xu et al.,
2016). More specifically, knee joints injected with senescent cells
exhibited severe articular cartilage damage at the lateral and medial
tibial plateaus, as well as the femoral condyles. This would suggest
targeting senescent cells might be an attractive therapeutic modality for
treatment of OA. However, it is not yet fully understood how the
mechanisms of chondrocyte senescence contribute to cartilage degra-
dation, and further mechanistic studies are urgently needed.
Senescence in the bone microenvironment
Recently senescent cells have been identified within the bone microen-
vironment (Farr et al., 2016). Comparing the presence of senescence
and SASP markers in young (6 month) and old (24 month) mice,
osteoblasts and osteocytes retrieved from trabecular and cortical skeletal
tissue in older animals showed an increase in expression of p16Ink4a, a
cell cycle inhibitor seen to increase with age (Krishnamurthy et al., 2004;
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Waaijer et al., 2012; Burd et al., 2013; Farr et al., 2016), concomitant
with an increase in senescent osteocytes present within the bone cortex.
Telomere dysfunction-induced foci were also more prevalent in osteo-
cytes from old mice. These findings suggest age-related bone loss could
be, in part, caused by cellular osteocyte senescence, given the vital role
of these cells in bone remodeling.
Autophagy
Autophagy is a cellular process thought to be a mechanism for cell
survival when cells become stressed, for example under hypoxia or
nutrient deprivation, in which cells degrade dysfunctional proteins and
macromolecules and recycle them to produce the necessary raw
materials for protein synthesis (Narita et al., 2011). There is an increasing
interest in the role of autophagy in cartilage biology; this process may
provide a key link between aging, cell survival, and OA. For instance,
autophagy appears to be constitutively active in articular cartilage but
decreases with age; an increase in apoptotic chondrocyte death was
associated with a decline in autophagy and increased cartilage damage
(Carames et al., 2010, 2015). Furthermore, chondrocyte-specific defi-
ciency of the autophagy factor ATG5 was recently shown to promote
age-related OA features in mice, concomitant with increased chondro-
cyte apoptosis (Bouderlique et al., 2016).
Advancing age is associated with dysregulated autophagy in cells
such as cardiac myocytes (Terman et al., 2003); this dysregulation
appears to result in oxidative stress and subsequent cellular senescence
(Wu et al., 2009; Toshima et al., 2014). It is possible that these processes
observed in other cell types also play a role in the cellular senescence
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Fig. 3 A comparison of the different characteristics observed in cell types found within joints of healthy subjects and patients with OA.
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observed in OA. Age-related loss of skeletal muscle is a major cause of
movement impairment during later stages of human life (Garcıa-Prat
et al., 2016). It is thought that stem cells in the muscle lose their
regenerative function as we age and contribute to structural and
functional decline of the muscle tissue, reviewed in detail (Grounds,
2014). In 2016, Garcıa-Prat et al. (2016) described in detail the
relationship between cell survival and autophagy in muscle stem/
progenitor cells, with physiologically aged satellite cells undergoing
senescence due to a decrease in autophagy. Young satellite cells entered
senescence due to increased mitochondrial dysfunction, oxidative stress,
and failure of proteostasis. By restoring the autophagy pathway in aged
cells, these workers were able to show the reversal of senescence and
restoration of regenerative functions (Garcıa-Prat et al., 2016). Extrap-
olating to the context of OA, this suggests that targeting improved
autophagy in joint tissues could provide a potential therapy that may
lead to a decrease in inflammation, along with enhanced regeneration of
joint tissues. This is a tempting idea given not only the poor regenerative
capacity of articular cartilage in OA, but also with regard to senescence
suppression strategies aimed at enhancing the capacity for potential use
of autologous chondrocyte populations for tissue regeneration/engi-
neering applications (Ashraf et al., 2016).
It is clear from the studies described above that an increased
understanding of the senescent program in relation to OA would provide
beneficial insight into the molecular mechanisms occurring within OA
joints, which could serve to broaden the spectrum of therapeutic
opportunities for the treatment of this debilitating disease. Furthermore,
a renewed effort to understand cellular senescence in joint tissues other
than cartilage might contribute to a more holistic view of the role of this
process in OA pathology.
Epigenetic changes in OA and cellular senescence
Both OA and cellular senescence are characterized by various epigenetic
changes thought to contribute to altered cellular phenotypes and disease
progression. Typically, epigenetic mechanisms can be clustered into
three categories: DNA methylation involving the methylation of CpG
islands; histone modifications such as acetylation, methylation, ubiqui-
tination, and phosphorylation; and regulatory micro RNAs (small
noncoding sequences involved in gene expression). We have already
discussed various striking similarities of senescent cells with cells found in
joint tissues during OA (particularly chondrocytes). In the following
section, we will discuss the role of epigenetic changes in the context of
OA, highlighting the similarities with those seen in senescence.
In human OA chondrocytes, DNA demethylation ofMMP13 promoter
region CpG sites is observed to enhance the expression of MMP-13 (Bui
et al., 2012), a key enzyme contributing to irreversible cartilage matrix
destruction. Furthermore, demethylation of the promoter sites of various
other matrix-degrading enzymes such as MMP-3, MMP-9 and a
disintegrin and metalloproteinase with thrombospondin motifs
(ADAMTS)-4 has been associated with their enhanced expression in
OA (Roach et al., 2005). Expression of MMP-3, an important proteolytic
activator of pro-collagenases, is extensively used as confirmation of the
senescent phenotype in vitro and is recognized as a ‘marker’ of
senescence. In fibroblasts, loss of DNA methylation activity may cause
p21-dependent cell cycle withdrawal and senescence (Young & Smith,
2001). Interestingly, chemically mediated DNA demethylation in chon-
drocytes induces terminal hypertrophic differentiation (Cheung et al.,
2001), a process essential to long bone growth in development that is
recapitulated during OA (von der Mark et al., 1992). Beyond a
commonality of enhanced MMP-13 expression (D’Angelo et al., 2000),
it is unclear whether there is any significant relationship between this
state and cellular senescence, although cellular hypertrophy has been
linked to senescence in fibroblasts (Demidenko & Blagosklonny, 2008).
It is yet to be determined whether changes in DNA methylation are
causative in OA or a consequence of the disease. In human mesenchymal
stem cells, workers have reported (Ezura et al., 2009) the presence of
low levels of DNA methylation at the CpG promoters of SOX9, whose
product maintains the chondrocyte phenotype (Lefebvre et al., 1997)
and RUNX2, whose product promotes chondrocyte hypertrophy (an
important factor in driving cartilage destruction) and subsequent
mineralization or apoptosis (von der Mark et al., 1992; Enomoto et al.,
2000; Yang et al., 2001; Cheung et al., 2003; Zheng et al., 2003;
Kamekura et al., 2006). While SOX9 and RUNX2 gene products are
critical master transcriptional regulators of chondrocyte differentiation,
profoundly regulating chondrogenesis and osteogenesis, the conse-
quences of differential methylation of their gene promoters in terms of
OA are as yet unclear.
Interleukin(IL)-1b, IL-6, and TNF-a, all present in the SASP of
senescent cells, are key pro-inflammatory cytokines associated with
OA. In addition to their confirmed role in driving destructive MMP
expression, IL-1b and TNF-a (in synergistic combination with the IL-6 type
cytokine, oncostatin M) have been shown to stimulate changes in the
methylation pattern of the IL1B gene (Hashimoto et al., 2009), leading
to potent and sustained mRNA induction. This then poses an important
question of how inflammatory stimuli alter the DNA methylation pattern
seen in OA. Could an influx or accumulation of senescent cells and their
SASP within the joints promote these epigenetic changes?
Interestingly, hypomethylation changes are also observed in senes-
cent cells, as well as in cancer. For example, Cruickshanks et al. (2013)
performed whole-genome single-nucleotide bisulfide sequencing on
human replicative senescent cells and showed widespread DNA
hypomethylation, as well as focal hypermethylation of senescent cells.
It is well known that one of the hallmarks of cancer is an alteration in
DNA methylation resulting in the destabilization of both genome
integrity and function (Matsuo et al., 1993; de Wind et al., 1995). In
human cancer cells, one of the first epigenetic alterations to be observed
was the low level of methylation in tumors when compared to non-
neoplastic cells (Feinberg & Vogelstein, 1983). As OA is an age-
associated disease, it is tempting to speculate that these strikingly similar
features of DNA methylation could reflect the involvement of senescence
gene expression programs in the pathogenesis of OA.
Gaining an understanding of the pathways and mechanisms involved
in epigenetic alterations, as well as investigating the effect of various
epigenetic drugs in the context of OA, would provide a promising future
research area with the potential of uncovering innovative therapeutic
advances. Such a method of treatment could potentially revolutionize
how age-related diseases such as OA are treated and possibly even
prevented in the future.
Future perspectives
This review explores the potential of the senescent phenotype to
predispose joint tissues to the development and/or progression of OA.
Senescent cells have the ability to synergize with inflammation and
inflammaging, already present within the OA joint microenvironment, to
drive further cellular senescent conversion and compound existing age-
related tissue damage, thus exacerbating and accelerating joint destruc-
tion. During OA, chondrocytes are seen to become ‘activated’ and
express a variety of senescence-associated markers. The exact mecha-
nism by which senescence of chondrocytes and especially other joint
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cells such as synovial fibroblasts, osteoblasts, and osteocytes contribute
to OA is not fully understood, although the accumulation of senescent
chondrocytes in the joints is widely thought to impair cartilage integrity.
Activated chondrocytes secrete a potent cocktail of cartilage-degrading
MMPs into the cartilage matrix, driving the development and progres-
sion of OA (Price et al., 2002). A study demonstrating the presence of
senescent osteoblasts and osteocytes within the bone microenvironment
of aged mice suggests an interesting potential to target these cell types
to delay, or even prevent, age-related bone loss (Farr et al., 2016).
Given this potential to play a key role in OA pathology, innovative
treatments could be developed by gaining an understanding of the
underlying mechanisms by which cellular senescence contributes to OA.
Recent studies have exposed numerous common characteristics between
OA cartilage and preneoplastic tissues, one of the most prevalent being
cellular senescence. These recent findings have inspired researchers to
explore the potential of using anticancer treatments to slow or prevent
the development and/or progression of OA.
Potential innovative therapeutic approaches
Senotherapeutic agents are used to target specific properties of cellular
senescence; more specifically, senolytics are used to target anti-
apoptotic mechanisms and induce cell death within senescent cells
(Zhu et al., 2015a,b; Chang et al., 2016). Senolytic drugs may therefore
also be potentially used to provide an innovative therapeutic approach to
treatment of various conditions. Dasatinib is currently used in the
treatment of cancer. It is widely accepted that cancer cells and senescent
cells share common anti-apoptotic characteristics, and the combination
treatment of dasatinib and quercetin has already been observed to
reduce the burden of senescent cells, as well as enhance cardiovascular
function, in aged mice (Zhu et al., 2015b). These workers reported, in
Ercc1/Δ mice exhibiting an accelerated aging condition, that periodic
administration of dasatinib and quercetin was seen to delay bone loss
and neurological dysfunction and to enhance health span (Zhu et al.,
2015b). We would emphasize that not all senolytic compounds are
anticancer and not all anticancer compounds are senolytic. Even among
senolytics there seems to be cell type specific responses, for example,
dasatinib is more effective in killing senescent human preadipocytes than
human umbilical vein endothelial cells (HUVECs), whereas quercetin is
effective in killing senescent HUVECs rather than senescent adipocytes.
More mechanistic work is needed to clarify the exact relationship of
senolytics to age-related disorders such as cancer and OA.
We have reviewed a body of work that, taken together, strongly
suggests that senescence could play a significant role in the pathogenesis
of OA. Therefore, if dasatinib/quercetin combination therapy is effective
in eliminating senescent cells, it could provide an extremely appealing
therapeutic target for OA. Although OA, unlike osteoporosis, involves
not loss but mostly local increases in bone synthesis, the bisphosphonate
anti-osteoporosis drug, alendronate, has been reported to ameliorate
experimental OA progression (Hayami et al., 2004). This suggests the
possibility that senolytic drugs could also be of therapeutic value in both
diseases, perhaps by preventing (likely via reducing inflammatory
signaling) aberrant bone metabolism.
Epigenetic alterations have cellular impacts potentially contributing to
OA development and progression, such as histone modifications that
regulate catabolic mediators in cartilage (Culley et al., 2013), and DNA
methylation present in genes known to regulate cartilage development
(Ezura et al., 2009). In RA, the effects of epigenetic drugs are already
being investigated. For instance, JQ1 is a BET bromodomain inhibitor
known to downregulate Myc transcription (Delmore Jake et al., 2011).
Myc is a transcription factor known to be upregulated in various cancers
as well as aiding in the growth and invasiveness of RA synovial fibroblasts
(RASFs) (Pap et al., 2004), a key cell type mediating joint inflammation
and destruction seen in RA (Bucala et al., 1991; Lefevre et al., 2009).
Recently, Zhang et al. (2015) showed that inhibition of bromodomain-
containing protein 4 (BRD4) by JQ1 caused a reduction in the
inflammatory response, joint damage, and also autoantibody production
in collagen-induced arthritis (CIA) murine models. Xiao et al. (2016)
further highlighted the therapeutic potential of JQ1 in inflammatory
arthritis, stating JQ1 decreased the proliferation of RASFs, as well as
decreasing the production of various cytokines, MMPs, and synovial
inflammation in CIA. These findings, although in the context of RA,
provide promising experimental evidence that targeting various epige-
netic alterations could be used in the future for OA treatment, especially
as synovial inflammation is now recognized to be a prominent feature of
OA. Further research into the effect of epigenetic alterations in OA offers
the potential to uncover novel pathways whose targeting could aid in
improved treatment, delayed progression, or even possible reversal of
OA.
Conclusion
The research of recent years has established that OA is not simply a
passive ‘wear and tear’ disorder, but rather a complex age-related
disease involving various different effectors, ranging from inflammatory
mediators to epigenetic alterations. This complexity has undoubtedly
contributed to the current lack of effective treatment options for OA,
with pain management and eventual joint replacement surgery a
common endpoint for a large proportion of patients. In this review,
we have highlighted the potential mechanisms by which senescent cells
can predispose joints of the body to the development and/or progression
of OA, and explored the potential of using senolytic drugs to target
senescent cells present in OA. In addition, targeting the epigenetic
alterations observed in OA provides a promising approach to treatment
as, unlike genetic changes, epigenetic changes can be reversed. In
conclusion, gaining a better understanding of molecular mechanisms by
which the senescence pathway and epigenetic changes underpin OA
pathogenesis could open up novel and innovative therapeutic
approaches.
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